Related Experiment Video
Updated: May 16, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Drug-induced dermatomyositis after zoledronic acid.
Philip L Tong1, Lawrence L Yu, Jonathan J Chan
1Department of Dermatology, Sir Charles Gairdner Hospital Dermatopathology WA School of Pathology and Laboratory Medicine, University of Western Australia, Perth, WA 6009, Australia. philipleitong@gmail.com
Zoledronic acid, used for osteoporosis, may cause dermatomyositis. This first report details a patient who developed muscle weakness and rash after zoledronic acid infusion.
Area of Science:
- Rheumatology
- Dermatology
- Pharmacology
Background:
- Osteoporosis management often involves bisphosphonates like zoledronic acid.
- Prior bisphosphonate exposure is noted in the patient's history.
Observation:
- A 57-year-old woman presented with myalgia, proximal muscle weakness, and a lichenoid rash.
- Symptoms appeared three days post-infusion of zoledronic acid.
- The rash affected the upper extremities and face.
Findings:
- Clinical, laboratory, and histological findings confirmed a diagnosis of dermatomyositis.
- This represents the first documented case of drug-induced dermatomyositis linked to zoledronic acid.
Implications:
- Highlights a potential adverse effect of zoledronic acid, necessitating vigilance in clinical practice.
- Suggests a need for further investigation into the immunogenic potential of bisphosphonates.
- Informs differential diagnosis in patients presenting with similar symptoms after zoledronic acid treatment.
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drug toxicity: Idiosyncratic Reactions
Myocarditis III: Medical Management
Drug Toxicity: Allergic Reactions
Myocarditis I: Introduction
